Psoriasis patients (n=20) showed significantly accelerated epigenetic aging compared to matched controls across four mortality-predictive DNA methylation clocks — PCGrimAge, GrimAge2, and two CpGPT variants — plus elevated DunedinPACE, a biomarker of biological aging speed. After 52 weeks of tildrakizumab-asmn (100 mg, an IL-23p19 inhibitor), PCGrimAge deviation reversed by approximately 0.5 years, with a statistically significant partial correction already visible at week 28 (0.3 years, P=0.005).
This finding matters beyond dermatology. Psoriasis has long been linked to elevated cardiovascular, metabolic, and all-cause mortality risk disproportionate to skin severity alone — a gap that inflammatory burden has only partly explained. Demonstrating that IL-23 inhibition moves epigenetic clocks in a rejuvenating direction adds a biological plausibility layer: chronic systemic inflammation may drive measurable molecular aging, and suppressing its upstream mediator can partially unwind that process. The GrimAge family of clocks carries some of the strongest validation linking DNAm to actual mortality outcomes in large longitudinal cohorts, lending credibility to the signal here.
Critical caveats apply heavily. Twenty treated patients in an open-label, industry-funded pilot without a placebo arm cannot establish causality or rule out regression to the mean. The 0.5-year reversal, while statistically significant, is modest in absolute terms. Whether these epigenetic shifts translate to clinical longevity benefit remains entirely unproven. Still, as a proof-of-concept, this is the rare study connecting targeted immunotherapy to epigenetic aging reversal — incremental but genuinely novel.
